neurocare is a Munich-based provider of a mental health platform that empowers clinicians to deliver personalized treatment across psychological and neurological conditions. Its platform embeds tools and methods such as sleep hygiene, rTMS, QEEG and neurofeedback alongside talk therapy and pharmaceuticals. These assets are integrated within a cloud-based solution designed to drive clinician productivity and improve clinical outcomes. Following a detailed assessment of a patient’s condition, the platform supports clinicians in developing individualized, scientifically backed therapy plans for Depression, ADHD, mental performance and other indications. The company intends to use recent funding to further develop its technologies and services and to expand the international footprint of its mental health clinics. neurocare is led by CEO Thomas Mechtersheimer and recently raised EUR 19.3M from external backers. neurocare provides an integrated, personalized treatment approach built around its Digital Therapy Platform (DTP), which supports clinicians in developing individualized therapy plans. The DTP combines psychotherapy, neuromodulation, sleep hygiene and medication to treat a variety of psychological and neurological conditions and to improve self-regulation, resilience and social skills. The platform is used in neurocare’s clinics across the US, the Netherlands and Australia, and is deployed in a growing number of third-party clinics. Led by CEO and founder Thomas Mechtersheimer, the company emphasizes clinically evidenced, cost-effective care for healthcare systems. neurocare plans to use the new funding to accelerate international growth — including US expansion and market entry into the Kingdom of Saudi Arabia — and to support development of new hardware and software innovations. The company recently raised EUR 16M to support these initiatives.

Total raised

$40M

Funding rounds

2

Latest round

Equity

Latest activity

Feb 2025